Compare Sanofi SA (SNY) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Teradyne, Inc. — how do they compare? Sanofi SA trades at $43.65 (market cap $104.30B), while Teradyne, Inc. trades at $404.71 (market cap $59.34B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | TER | |
|---|---|---|
Market Cap | $104.30B | $59.34B |
Sector | Health | Technology |
52-Week High | $52.34 | $483.84 |
52-Week Low | $41.33 | $109.30 |
Enterprise Value | $124.19B | $59.09B |
Dividend Yield | 5.55% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Teradyne (TER) is trading at $402.65, up 10.28% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows robust fundamentals with record revenue of $1.3 billion in Q2, net income margin of 25.77%, and consistent earnings beats. Technical indicators suggest bullish momentum with the current price near resistance at $400, while analyst consensus remains strongly positive with a $481.63 price target.
Outlook remains positive driven by AI-led semiconductor test demand and robotics growth, though elevated valuation multiples (P/E 52.14) and market volatility present risks. The company's strong guidance and institutional support suggest continued upside potential, but investors should monitor competitive pressures in the semiconductor equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
